NYSE Arca · VNRX
VolitionRX Limited
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VNRX: Nov 12, 2026
VolitionRX Limited Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.35. The reported EPS for the same quarter last year was $-0.8.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Dec 2026 | $-0.19 | $-0.19 | $-0.19 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool- Fintel · Oct 27, 10:58 PM EDTVolitionRx Limited Announces $500,000 Partial Prepayment of Convertible NoteVolitionRx Limited entered into a waiver and consent on October 23, 2026, with Lind Global Asset Management XII LLC regarding a senior secured convertible promissory note issued January 15, 2026, in the original principal amount of $2,400,000. The note was originally issued pursu
- Fintel · Oct 2, 8:49 AM EDTVolitionRx Consensus Price Target Decreased by 17.44% to $13.89The average one-year price target for VolitionRx (NYSEAM:VNRX) has been revised to $13.89 / share. This is a decrease of 17.44% from the prior estimate of $16.83 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute
- RTTNews · Aug 26, 10:00 AM EDTVolition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down(RTTNews) – VolitionRx Limited (VNRX) announced landmark clinical validation of its Nu.Q NETs biomarker in sepsis, with findings published in Critical Care Medicine. The study confirmed that, Nu.Q NETs is an independent predictor of 28-day mortality and the need for renal replace
- The Motley Fool · Aug 20, 7:28 PM EDTVolition (VNRX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · May 14, 12:37 AM EDTVolitionRx (VNRX) Price Target Increased by 1,618.09% to 29.79The average one-year price target for VolitionRx (NYSEAM:VNRX) has been revised to $29.79 / share. This is an increase of 1,618.09% from the prior estimate of $1.73 dated April 25, 2026. The price target is an average of many targets provided by analysts. The
- Fintel · Apr 28, 11:17 AM EDTVolitionRx (VNRX) Price Target Decreased by 17.48% to 1.73The average one-year price target for VolitionRx (NYSEAM:VNRX) has been revised to $1.73 / share. This is a decrease of 17.48% from the prior estimate of $2.10 dated April 12, 2026. The price target is an average of many targets provided by analysts. The lates
- RTTNews · Mar 25, 9:49 AM EDTVolition's Capture-Seq Shows Over 95% Detection Of Early-Stage Cancers; Stock Up(RTTNews) – VolitionRx Limited's (VNRX) breakthrough liquid biopsy technology, Capture-Seq, has delivered striking proof-of-concept results, detecting more than 95% of stage I and stage II cancers in a blinded validation cohort.
- RTTNews · Jan 30, 11:04 AM ESTVolition Advances Nu.Q Cancer Assay Program With Reimbursement Submission In France(RTTNews) – VolitionRx Limited (VNRX) announced that it has begun preparing a reimbursement submission for its Nu.Q Cancer assays in France, marking a significant step toward broader clinical adoption of its nucleosome-based diagnostic technology.
- Fintel · Dec 21, 11:39 AM ESTVolitionRx (VNRX) Price Target Decreased by 13.33% to 2.21The average one-year price target for VolitionRx (NYSEAM:VNRX) has been revised to $2.21 / share. This is a decrease of 13.33% from the prior estimate of $2.55 dated December 3, 2025. The price target is an average of many targets provided by analysts. The lat
- Fintel · Dec 18, 10:35 AM ESTD. Boral Capital Maintains VolitionRx (VNRX) Buy RecommendationFintel reports that on December 18, 2025, D. Boral Capital maintained coverage of VolitionRx (NYSEAM:VNRX) with a Buy recommendation. Analyst Price Forecast Suggests 854.70% Upside
- Fintel · Dec 6, 6:37 AM ESTVolitionRx (VNRX) Price Target Decreased by 25.65% to 2.55The average one-year price target for VolitionRx (NYSEAM:VNRX) has been revised to $2.55 / share. This is a decrease of 25.65% from the prior estimate of $3.43 dated November 14, 2025. The price target is an average of many targets provided by analysts. The la
- Fintel · Nov 17, 7:04 PM ESTHC Wainwright & Co. Maintains VolitionRx (VNRX) Buy RecommendationFintel reports that on November 17, 2025, HC Wainwright & Co. maintained coverage of VolitionRx (NYSEAM:VNRX) with a Buy recommendation. Analyst Price Forecast Suggests 967.79% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for VolitionRX Limited from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.